☆ 4.5 Article

The Emerging Role of Lapatinib in HER2-positive Breast Cancer

CURRENT ONCOLOGY REPORTS (2008)

期刊

CURRENT ONCOLOGY REPORTS

卷 10, 期 1, 页码 10-17

出版社

SPRINGER

DOI: 10.1007/s11912-008-0004-0

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

摘要

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Pharmacology & Pharmacy

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells

Min Ye, Wei Huang, Rui Liu, Yingli Kong, Yang Liu, Xiaole Chen, Jianhua Xu

Summary: The study demonstrated that the combination treatment of ganetespib and lapatinib has synergistic inhibitory effects on HER2-positive breast cancer cells, enhancing antitumor activity through multiple pathways.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Oncology

Emerging Targeted Therapies for HER2-Positive Breast Cancer

Maria Florencia Mercogliano, Sofia Bruni, Florencia Luciana Mauro, Roxana Schillaci

Summary: Breast cancer is a common and deadly disease, with HER2 overexpression being associated with a poor prognosis. While trastuzumab is the standard treatment, many patients do not respond to it. Other HER2-targeted therapies, such as pertuzumab, margetuximab, and T-DM1, as well as tyrosine kinase inhibitors, have been developed. Combination therapies with immune checkpoint inhibitors, CAR-T cells, CAR-NK cells, CAR-M cells, and vaccines are also being explored. This review discusses the different HER2-targeted therapies and potential combinations to overcome resistance.

CANCERS (2023)

添加到收藏夹

Article Oncology

Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer

Xiaolin Sang, Li Li, Chunhua Rui, Yichao Liu, Zundong Liu, Zhiwei Tao, Hailing Cheng, Pixu Liu

Summary: The study demonstrates that melatonin can enhance the sensitivity of HER2-positive breast cancer cells to lapatinib by promoting excessive endoplasmic reticulum stress-induced unfolded protein response and ROS accumulation. Additionally, melatonin also boosts the anti-tumor effect of lapatinib in HER2-positive breast cancer.

CANCER LETTERS (2021)

添加到收藏夹

Review Oncology

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

Ilana Schlam, Sandra M. Swain

Summary: HER2-positive breast cancer accounts for a significant proportion of cases, with several targeted therapies available including TKIs which have shown promising responses in both early and advanced settings. In patients with central nervous system involvement, TKIs have shown efficacy, which is important for those with limited treatment options and poor prognosis in this setting.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Oncology

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study

Guilherme Nader-Marta, Veronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja

Summary: The sub-analysis of the ALTTO trial demonstrates that patients with small node-negative breast cancer treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Review Oncology

The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer

Vladimir Tolmachev, Anna Orlova, Jens Sorensen

Summary: Targeting of HER2 using monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors has shown success in extending survival of metastatic breast cancer patients with HER2-expressing tumors, with high HER2 expression serving as a predictive biomarker for such targeted therapies. Accurate determination of HER2 expression level is crucial for patient stratification, and non-invasive in vivo radionuclide molecular imaging of HER2 offers the potential for repetitive measurements to address issues of heterogeneous expression and changes in HER2 status during disease progression or treatment response.

SEMINARS IN CANCER BIOLOGY (2021)

添加到收藏夹

Article Oncology

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou

Summary: The study assessed the efficacy and safety of pyrotinib plus capecitabine in HER2-positive metastatic breast cancer patients after trastuzumab. The interim analysis showed that pyrotinib plus capecitabine significantly improved progression-free survival compared to lapatinib plus capecitabine, with manageable toxicity. This treatment could be considered as an alternative option for patients in this setting.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer

Xiaoyu Chen, Ying Li, Zhiwei Zhou, Yanqiu Zhang, Luchen Chang, Xiujun Gao, Qing Li, Hao Luo, Kenneth D. Westover, Jialin Zhu, Xi Wei

Summary: This study firstly found that reversible senescence contributed to lapatinib (LAP) resistance in HER2+ breast cancer and identified ecto-5'-nucleotidase (NT5E) as a marker of reversible senescence in HER2+ breast cancer. We constructed NT5E targeted nanobubbles (NT5E-FITC-NBs) as a new molecular imaging modality which could both target reversible senescent cells and be used for ultrasound imaging. Cellular senescence-based ultrasound targeted imaging could identify reversible senescence early and evaluate LAP resistance effectively in HER2+ breast cancer.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer

Francesca Ligorio, Ilaria Pellegrini, Lorenzo Castagnoli, Andrea Vingiani, Riccardo Lobefaro, Emma Zattarin, Marzia Santamaria, Serenella M. Pupa, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri

Summary: De novo or acquired resistance to currently available HER2 inhibitors in cancer cells poses a challenge in clinical practice. Inhibiting fatty acid biosynthesis and uptake may be a potential strategy to overcome resistance to anti-HER2 therapies in HER2+ breast cancer patients. Ongoing clinical trials are investigating the combination of inhibiting FA metabolism with HER2 inhibitors in this patient population.

CANCER LETTERS (2021)

添加到收藏夹

Review Oncology

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Zhen-hao Wang, Zhuo-qun Zheng, Shi-cheng Jia, Shu-ni Liu, Xiao-fen Xiao, Guan-yuan Chen, Wei-quan Liang, Xiao-feng Lu

Summary: Trastuzumab is a standard targeted therapy for HER2-positive breast cancer, but the issue of resistance limits its efficacy. This study described the underlying molecular mechanisms of trastuzumab resistance and summarized potential biomarkers and therapeutic strategies.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

miR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer

Thanh Kieu Huynh, Chih-Hao Huang, Jhen-Yu Chen, Jin-Han Yao, Yi-Shiang Yang, Ya-Ling Wei, Hsiao-Fan Chen, Chia-Hung Chen, Chih-Yen Tu, Yuan-Man Hsu, Liang-Chih Liu, Wei-Chien Huang

Summary: The study revealed that elevation of miR-221 targeting p27(kip1) contributes to the development of acquired resistance to lapatinib in HER2-positive breast cancer, with Src inhibition suggested as a potential strategy to overcome this resistance.

CANCER SCIENCE (2021)

添加到收藏夹

Review Oncology

Clinical trial data and emerging strategies: HER2-positive breast cancer

Sonia Pernas, Sara M. Tolaney

Summary: An understanding of tumor biology and HER2 signaling has led to the development of effective anti-HER2 drugs, improving the prognosis of patients with HER2-positive breast cancer. The immune microenvironment and host immune system also play important roles in prognosis and treatment response. This review presents the latest evidence and emerging strategies of immunotherapy in HER2-positive breast cancer.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+Breast Cancer

Ana Carla Castro-Guijarro, Angel Matias Sanchez, Marina Ines Flamini, Christoph F. A. Vogel

Summary: This study aims to identify biomarkers for predicting disease progression and therapy efficacy in HER2-positive breast cancer, as well as to overcome resistance. Combining anti-HER2 therapies shows potential in inhibiting cell adhesion and migration critical for cancer metastasis. Deregulated proteins in resistant cells may serve as potential biomarkers of therapy response and resistance. These findings are promising for personalized breast cancer management to maximize the safety and efficacy of anti-HER2 therapies.

CANCERS (2023)

添加到收藏夹

Article Multidisciplinary Sciences

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

Avisek Majumder, Manbir Sandhu, Debarko Banerji, Veronica Steri, Adam Olshen, Mark M. Moasser

Summary: HER2-amplified cancers are dependent on HER2 across different cancer types, with the level of addiction linked to the expression level of HER2 rather than HER3. The expression and phosphorylation of HER3 vary in HER2-amplified cancer cells from different tissues, and HER3 plays an essential role in tumorigenic growth in some tumors. More biomarkers will be needed to guide the optimal use of HER3 inhibitors in HER2-amplified cancers from non-breast origin.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Xin Hua, Xi-Wen Bi, Jian-Li Zhao, Yan-Xia Shi, Ying Lin, Zhi-Yong Wu, Yuan-Qi Zhang, Le-Hong Zhang, An-Qing Zhang, Heng Huang, Xin-Mei Liu, Fei Xu, Ying Guo, Wen Xia, Ruo-Xi Hong, Kui-Kui Jiang, Cong Xue, Xin An, Yong-Yi Zhong, Shu-Sen Wang, Jia-Jia Huang, Zhong-Yu Yuan

Summary: This study aimed to compare the efficacy of endocrine therapy and chemotherapy as partner strategies with anti-HER2 therapy for first-line treatment of HR(+)HER2(+) metastatic breast cancer. The results showed that trastuzumab plus endocrine therapy was noninferior to trastuzumab plus chemotherapy in terms of progression-free survival, with a significantly higher prevalence of toxicity in the chemotherapy group.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

Kathy S. Albain, Robert J. Gray, Della F. Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer, Elizabeth C. Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil S. Badve, Thomas J. Saphner, Lynne Wagner, Timothy J. Whelan, Matthew J. Ellis, William C. Wood, Maccon M. Keane, Henry L. Gomez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam M. Brufsky, Deborah L. Toppmeyer, Virginia G. Kaklamani, Jeffrey L. Berenberg, Jeffrey Abrams, George W. Sledge, Joseph A. Sparano

Summary: The study revealed that black women with early breast cancer had worse clinical outcomes despite similar 21-gene recurrence score results and comparable systemic therapy. Hispanic ethnicity and Asian race were associated with better outcomes.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Oncology

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial

Otto Metzger Filho, Daniel G. Stover, Sarah Asad, Peter J. Ansell, Mark Watson, Sibylle Loibl, Charles E. Geyer Jr, Junu Bae, Katharine Collier, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans

Summary: Adding carboplatin to standard neoadjuvant chemotherapy in triple-negative breast cancer may benefit a subset of patients, with tumor cell proliferation and immune scores identified as independent factors associated with achieving pathologic complete response. Further validation of immunophenotype with existing biomarkers may help guide therapy for TNBC patients.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

E. P. Mamounas, M. Untch, M. S. Mano, C-S Huang, C. E. Geyer, G. von Minckwitz, N. Wolmark, X. Pivot, S. Kuemmel, M. P. DiGiovanna, B. Kaufman, G. Kunz, A. K. Conlin, J. C. Alcedo, T. Kuehn, I Wapnir, A. Fontana, J. Hackmann, J. Polikoff, M. Saghatchian, A. Brufsky, Y. Yang, M. Zimovjanova, T. Boulet, H. Liu, D. Tesarowski, L. H. Lam, C. Song, M. Smitt, S. Loibl

Summary: T-DM1 shows good safety and efficacy in patients with HER2-positive EBC, benefiting different subgroups without increasing the risk of central nervous system recurrence.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge

Christian Jackisch, Patricia Cortazar, Charles E. Geyer Jr, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart

Summary: Treatment of HER2-positive early breast cancer involves neoadjuvant and adjuvant targeted therapies, with key decision points being the choice of appropriate treatment approach and planning of subsequent therapy based on the pathological response to neoadjuvant treatment.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Oncology

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John P. Crown, Michael P. Thirlwell, David M. Ellison, Jean-Francois Boileau, Patrick J. Flynn, Jong-Hyeon Jeong, Eleftherios P. Mamounas, Norman Wolmark

Summary: The NRG Oncology/NSABP B-47 menstrual history study investigated the impact of trastuzumab on menstrual status and reproductive hormone levels. Results revealed that trastuzumab did not lead to a higher rate of amenorrhea, and confirmed previous findings regarding predictors of amenorrhea. This large prospective study provided valuable data for counseling patients on the risk of premature menopause.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Oncology

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

C. E. Geyer, W. M. Sikov, J. Huober, H. S. Rugo, N. Wolmark, J. O'Shaughnessy, D. Maag, M. Untch, M. Golshan, J. Ponce Lorenzo, O. Metzger, M. Dunbar, W. F. Symmans, P. Rastogi, J. H. Sohn, R. Young, G. S. Wright, C. Harkness, K. McIntyre, D. Yardley, S. Loibl

Summary: This study demonstrates that the addition of carboplatin to neoadjuvant chemotherapy can improve the pathological complete response rates in patients with triple-negative breast cancer without increasing the risk of side effects or secondary malignancies.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

Patricia A. Ganz, Hanna Bandos, Charles E. Geyer, Andre Robidoux, Alexander H. G. Paterson, Jonathan Polikoff, Luis Baez-Diaz, Adam M. Brufsky, Louis Fehrenbacher, Ann W. Parsons, Patrick J. Ward, Louise Provencher, John T. Hamm, Philip J. Stella, Robert L. Carolla, Richard G. Margolese, Henry R. Shibata, Edith A. Perez, Norman Wolmark

Summary: This study compared the efficacy of AC and FEC-100 in the treatment of breast cancer. The results showed that the AC group had better quality of life during chemotherapy, while the FEC-100 group had a higher rate of amenorrhea. After 12 months of treatment, there were no significant differences in quality of life between the two groups.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover

Summary: In the study, adding carboplatin +/- veliparib to neoadjuvant chemotherapy did not increase the odds of pathologic complete response in BRCA1/2 mutation carriers compared to non-carriers. Additionally, molecular, immune, chromosomal instability, and proliferation gene expression metrics did not show significant differences between the two groups.

NPJ BREAST CANCER (2021)

添加到收藏夹

Letter Oncology

Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okines and N. Turner

C. E. Geyer, W. M. Sikov, S. Loibl

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Charles E. Geyer, Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, Andre Robidoux, Louis Fehrenbacher, Patrick J. Ward, Jonathan Polikoff, Adam M. Brufsky, Louise Provencher, Alexander H. G. Paterson, John T. Hamm, Robert L. Carolla, Luis Baez-Diaz, Thomas B. Julian, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark

Summary: This study compared the efficacy of 6 cycles of FEC-100 with celecoxib or placebo to 4 cycles of AC in node-negative breast cancer patients. The results showed that FEC-100 did not improve DFS compared to AC, but had a significant differential effect in receptor-positive patients. FEC-100 treatment was associated with expected increases in toxicity.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lubbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark

Summary: In HER2-negative breast cancer patients, T-DM1 treatment may be more effective than trastuzumab.

NPJ BREAST CANCER (2022)

添加到收藏夹

Letter Medicine, General & Internal

Adjuvant Olaparib in BRCA-Mutated Breast Cancer REPLY

Andrew N. J. Tutt, Judy E. Garber, Charles E. Geyer

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Meeting Abstract Oncology

21-Gene Recurrence Score Predictive for Patients Most Likely to Benefit From Postoperative Radiation Following Breast Conserving Surgery for T1N0 Breast Cancer

N. C. Chevli, W. Haque, K. T. Tran, A. M. Farach, M. R. Schwartz, C. E. Geyer, S. S. Hatch, E. B. Butler, B. S. Teh

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Correction Surgery

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (vol 155, e195410, 2020)

Mehra Golshan, Sibylle Loibl, Stephanie M. Wong, Jens Bodo Houber, Joyce O'Shaughnessy, Hope S. Rugo, Norman Wolmark, Mark D. McKee, David Maag, Danielle M. Sullivan, Otto Metzger-Filho, Gunter Von Minckwitz, Charles E. Geyer, William M. Sikov, Michael Untch

JAMA SURGERY (2021)

添加到收藏夹

Article Oncology

Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic

Jorge G. Darcourt, Kalia Aparicio, Phillip M. Dorsey, Joe E. Ensor, Eva M. Zsigmond, Stephen T. Wong, Chika F. Ezeana, Mamta Puppala, Kirk E. Heyne, Charles E. Geyer, Robert A. Phillips, Roberta L. Schwartz, Jenny C. Chang

Summary: The study evaluated the use of telemedicine in cancer patients during the SARS-CoV-2 pandemic and found high levels of satisfaction among both patients and physicians. However, barriers to its implementation were identified, particularly among older, low-income, and underinsured patient populations. Physicians expressed concerns about inadequate patient interactions, potential for missing clinical findings, decreased quality of care, and medical liability issues with the use of telehealth technology.

JCO ONCOLOGY PRACTICE (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.